Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Santen Pharmaceutical Co ( (JP:4536) ).
Santen Pharmaceutical Co. has announced the suspension of its planned disposal of treasury shares for a performance-linked stock remuneration plan due to the aggregate amount exceeding 100 million yen. The company has withdrawn its previous securities notice and will provide further details once the Board of Directors finalizes their decisions.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen2600.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company focused on eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen is engaged in research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,398,379
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen559.8B
For an in-depth examination of 4536 stock, go to TipRanks’ Overview page.